Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 4,241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Deficiency Disorder Clear all
Completed Not applicable Interventional Results available

High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV

NCT04550676
View directory record Official record
Conditions
Hiv, Fatigue, Mobility Limitation
Interventions
HIIT (intervention), CME (active control), Coaching, Control text message
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 17, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional Results available

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

NCT04893018
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, HIV Infection, Kaposi Sarcoma
Interventions
Efineptakin alfa
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
San Francisco, California • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Vitamin D Supplementation in HIV Youth

NCT01523496
View directory record Official record
Conditions
HIV Infections
Interventions
Vitamin D control dose, Vitamin D supplementation-
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
8 Years to 25 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up

NCT00001476
View directory record Official record
Conditions
Chronic Granulomatous Disease, Communicable Disease
Interventions
Gene Therapy Method for CGD, Isolex 300i Magnetic Cell Selector
Drug · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Not applicable Interventional

A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients

NCT00002013
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, AS-101
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 3 Interventional

Motivation and Patch Treatment for HIV-positive Smokers

NCT00551720
View directory record Official record
Conditions
HIV Infections, Smoking Cessation
Interventions
Standard Care, Motivational Enhancement
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
5
States / cities
Fall River, Massachusetts • New Bedford, Massachusetts • Pawtucket, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 4 Interventional

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

NCT00106379
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada (tenofovir DF + emtricitabine), Emtriva (emtricitabine), Viread (tenofovir DF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Vero Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Oct 17, 2026, 2:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Access to Care Study (FACS)

NCT00582218
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

NCT00819390
View directory record Official record
Conditions
HIV Infections
Interventions
Chloroquine, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Bioequivalence of a Combined Formulated Tablet

NCT01622790
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Interventions
Raltegravir, Atazanavir, Standard treatment regimen
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

NCT01209117
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus
Interventions
GSK2248761 WBM Capsule, GSK2248761 WBM Tablet Formulation 1, GSK2248761 WBM Tablet Formulation 2, GSK2248761 WBM Tablet Formulation 3, GSK2248761 WBM Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 17, 2026, 2:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Not applicable Interventional

A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH)

NCT01198418
View directory record Official record
Conditions
Sexually Transmitted Infections, HIV Infections
Interventions
Experimental
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 17, 2026, 2:17 AM EDT
Terminated Not applicable Interventional Results available

Antiretroviral Improvement Among Medicaid Enrollees

NCT05477485
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Experimental: AIMS program - patient, No Intervention/Usual care
Behavioral · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
19 Years to 64 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

NCT00622843
View directory record Official record
Conditions
HIV Infections, Streptococcus Pneumoniae
Interventions
pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
6
States / cities
San Diego, California • Washington D.C., District of Columbia • Tripler AMC, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Social Capital and Engagement in Care Among Young Black Men Who Have Sex With Men Living With HIV

NCT03664817
View directory record Official record
Conditions
HIV Infections
Interventions
social capital intervention, group-based health promotion intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 17, 2026, 2:17 AM EDT
Completed No phase listed Observational

Evaluation of Barriers to Postpartum Care in HIV Infected Women

NCT01853917
View directory record Official record
Conditions
HIV Infection, Pregnancy
Interventions
questionaires and structured interviews
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-exposure Prophylaxis Implementation in Central-Eastern European Countries

NCT05323123
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
SPARK, HealthMpowerment, PrEP Education
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 3 Interventional

Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

NCT00002070
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Sargramostim, Ganciclovir
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women

NCT00594373
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir gel, Tenofovir gel placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 2:17 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Using Heavy Water to Study Cell Dynamics in Parkinson's Disease

NCT00990379
View directory record Official record
Conditions
Parkinson's Disease, HIV Infections
Interventions
Not listed
Lead sponsor
Salena Killion
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 17, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

NCT00631566
View directory record Official record
Conditions
HIV Infections, Staphylococcal Infections
Interventions
Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
4
States / cities
San Diego, California • Bethesda, Maryland • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 17, 2026, 2:17 AM EDT